COMPANY INTELLIGENCEWhat the linked records show
MedtechLedger currently links 2 FDA records to the applicant name Perimeter Medical Imaging Ai, Inc.. It includes 1 original PMA approval. 1 entry is a PMA supplement. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Mar 3, 2026 to Aug 10, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code SHH appears in 2 of the 2 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P250008, with 2 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes.
Applicant mailing address recorded by FDA: 555 Richmond St. W, Suite 511, Toronto, M5V 3B1. Recorded on P250008/S001, decision dated Aug 10, 2026.
Device categories in this collection
OCT imaging system with AI/ML software for adjunctive detection of breast cancer.
Changes described in PMA records
FDA’s recorded scope: Approval for a manufacturing site located at RBC Development, LLC (dba Vantage MedTech / RBC Medical Innovations), located at 17100 W 118th Terrace, Olathe, KS 66061, performing cart assembly, consumable (Specimen Immobilizer) assembly, receiving inspection, and tech services and laboratory functions at this facility.
Aug 10, 2026 · Normal 180 Day Track No User FeeFDA’s recorded scope: The Claire OCT System is an adjunctive three-dimensional imaging tool which provides volumetric cross-sectional, real-time depth visualization, coupled with an artificial intelligence computer-aided detection algorithm which identifies and marks focal areas suspicious for breast cancer and is used concurrently with physician interpretation of the images. The Claire OCT System is intended for use in conjunction with other standard methods for evaluation of the margins of excised lumpectomy tissue during surgical procedures in patients with a biopsy-confirmed diagnosis of breast cancer.
Mar 3, 2026Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.